Skip to main content
OpenTrials
Completed

NCT Number: NCT03411070

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery. The SCOUT localization system with the SAVI reflector is non-radioactive and completely internal so can be placed into an abnormal lymph node prior to chemotherapy treatment, which theoretically will allow easier identification and therefore more reliable targeting of the abnormal lymph node for surgical removal.

Completed

Looking for future studies?

Notify Me

Key information

About this study

PRIMARY OBJECTIVES:

I. Percentage of patients with successful retrieval of the reflector confirmed by specimen radiography.

II. Percentage of patients with successful retrieval of the biopsied node, confirmed by presence of clip, biopsy changes or treatment-related changes on pathology.

SECONDARY OBJECTIVES:

I. Total number of lymph nodes removed. II. Percentage of patients in which clipped node was a sentinel node. III. Percentage of patients with nodal pathologic complete response (PCR). IV. Residual cancer burden (RCB) score for patients with residual nodal disease.

V. Percentage of patients requiring axillary dissection. VI. Days prior to surgery of reflector insertion.

OUTLINE:

Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to give written informed consent to participate in the study
  • Patients with a breast cancer diagnosis of any subtype and a biopsy-proven positive axillary lymph node who will be treated first with chemotherapy
  • Enlarged lymph node and/or clip targetable with image guidance
  • Patients who are eligible for surgical resection of the primary breast cancer and targeted dissection of the axilla

Exclusion criteria

  • More than 3 positive axillary nodes on imaging or matted nodes on clinical exam
  • Stage IV breast cancer
  • Pregnant or lactating females
  • Patients with inflammatory breast cancer
  • Patients with allergies to isosulfan blue or technetium, which would preclude sentinel node mapping
  • Patients who have had previous axillary surgery, including sentinel lymph node biopsy

Treatment and study plan

Implanted Medical Device

Device

Undergo SCOUT reflector placement

Other names: IMPLANTED

therapeutic conventional surgery

Procedure

Undergo surgery

Primary outcomes

  1. Percentage of patients with successful retrieval of reflector confirmed by specimen radiography

    Time frame: Up to 2 years

  2. Percentage of patients with successful retrieval of the biopsied node, confirmed by presence of clip, biopsy changes or treatment-related changes on pathology

    Time frame: Up to 2 years

Secondary outcomes

  1. Total number of lymph nodes removed

    Time frame: Up to 2 years

  2. Percentage of patients in which clipped node was a sentinel node

    Time frame: Up to 2 years

  3. Percentage of patients with nodal pathologic complete response (PCR)

    Time frame: Up to 2 years

  4. Residual cancer burden (RCB) score for patients with residual nodal disease

    Time frame: Up to 2 years

  5. Percentage of patients requiring axillary dissection

    Time frame: Up to 2 years

  6. Days prior to surgery of tag insertion

    Time frame: Up to 2 years

  7. Incidence of adverse events

    Time frame: Up to 2 years

    All adverse events due to these procedures will be recorded and reported to the institutional review board (IRB).

Sponsors and collaborators

Lead sponsor

Jonsson Comprehensive Cancer Center

Other

Collaborators

  • Faxitron bioptics, LLC

Registry information

Official study title

Using Radar Technology to Tag Abnormal Lymph Nodes for Removal During Surgery Following Neoadjuvant Chemotherapy

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 25, 2018
Registry last updated
Jan 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.